Transcell Technologies Inc. other research news

The majority-owned subsidiary of Interneuron Pharmaceuticals Inc. (IPIC) received a$100,000 Phase I SBIR from the National Institute for Allergy and Infectious Disease to evaluate the effectiveness o...